2020 / 01

Next Paper
DOI: 10.24075/brsmu.2020.001

ORIGINAL RESEARCH

Isoniazid-resistant Mycobacterium tuberculosis: prevalence, resistance spectrum and genetic determinants of resistance

Andreevskaya SN, Smirnova TG, Larionova EE, Andrievskaya IYu, Chernousova LN, Ergeshov A
About authors

Laboratory of Biotechnology, Central Tuberculosis Research Institute, Moscow, Russia

Correspondence should be addressed: Sofia N. Andreevskaya
Yauzskaya alley, 2, Moscow, 107564; ur.liam@aifosdna

About paper

Funding: this study was supported by the Ministry of Science and Higher Education of the Russian Federation and carried out under the Federal Targeted Program for Research and Development in Priority Areas of Development of the Russian Scientific and Technological Complex for 2014-2020, Project № 05.586.21.0065 (Project ID RFMEFI58619X0065).

Author contribution: Ergeshov A, Chernousova LN — study design; Larionova EE, Andrievskaya IYu — data acquisition; Smirnova TG — data analysis; Andreevskaya SN — manuscript preparation, literature analysis. All authors have equally contributed to the discussion of the obtained results.

Received: 2019-12-11 Accepted: 2020-01-07 Published online: 2020-01-12
|
  1. Order of the Ministry of Health of the Russian Federation of 9 December 2014 «Ob utverzhdenii metodicheskikh rekomendatsiy po sovershenstvovaniyu diagnostiki i lecheniya tuberkuleza organov dykhaniya». Russian.
  2. World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization; 2018. (WHO/CDS/TB/2018.20).
  3. Nechaeva OB. TB situation Russiania. Tuberculosis and Lung Diseases. 2018; 96 (8): 15–24. Russian.
  4. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019 (WHO/CDS/TB/2019.33).
  5. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009; (13): 1320–30.
  6. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS Med. 2009; 6 (2): e2.
  7. Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2017; 17 (2): 223–34.
  8. World Health Organization. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. Geneva: World Health Organization; 2018 (WHO/CDS/TB/2018.7).
  9. Siddiqi SH, Rusch-Gerdes S. MGIT procedure manual for BACTEC MGIT 960 TB System. 2006.
  10. Chernousova LN, Smirnova TG, Larionova EE, i dr. Standartnyye operatsionnyye protsedury. Opredeleniye chuvstvitel'nosti mikobakteriy tuberkuleza k protivotuberkuleznym preparatam vtorogo ryada s ispol'zovaniyem sistemy BACTEC MGIT 960/320. Moscow, 2015. Russian.
  11. Jenkins HE, Zignol M, Cohen T. Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009. PLoS ONE. 2011; 6 (7): e22927.
  12. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 2009; 6 (9): e1000146.
  13. Jeon CY, Hwang SH, Min JH, Prevots DR, Goldfeder LC, Lee H, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis. 2008; (46): 42–9.
  14. Bang D, Andersen PH, Andersen AB, Thomsen VØ. Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome. J Infect. 2010; 60 (6): 452–7.
  15. Salindri AD, Sales RF, DiMiceli L, Schechter MC, Kempker RR, Magee MJ. Isoniazid monoresistance and rate of culture conversion among patients in the state of Georgia with confirmed tuberculosis, 2009–2014. Ann Am Thorac Soc. 2018; 15 (3): 331–40.
  16. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM, et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis. 2009; 48 (2): 179–85.
  17. Tolani MP, D’souza DT, Mistry NF. Drug resistance mutations and heteroresistance detected using the GenoType MTBDRplus assay and their implication for treatment outcomes in patients from Mumbai, India. BMC Infect Dis. 2012; (12): 9.
  18. Huyen MN, Cobelens FG, Buu TN, Lan NT, Dung NH, Kremer K, et al. Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes. Antimicrob Agents Chemother. 2013; 57 (8): 3620–7.
  19. Stagg HR, Harris RJ, Hatherell HA, Obach D, Zhao H, Tsuchiya N, et al. What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis. Thorax. 2016; 71 (10): 940–9.
  20. World Health Organization. WHO meeting report of a technical expert consultation: non–inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. Geneva: World Health Organization; 2017. WHO/HTM/TB/2017.04. Available from: https://www.who. int/tb/publications/2017/XpertUltra/en/. Accessed: 18 May 2019.